Data on Delandistrogene Moxeparvovec Can Inform Future Gene Therapies

The FDA approved delandistrogene moxeparvovec-rokl (Elevidys, Sarepta Therapeutics) in June to treat Duchenne muscular dystrophy in ambulatory pediatric patients aged 4 through 5 who have a confirmed DMD gene mutation.

Related Keywords

,Methods Clinical Development ,National Organization For Rare Disorders ,Sarepta Therapeutics ,Molecular Therapy ,Image Credit ,Ther Methods Clin ,Updated June ,Updated August ,Delandistrogene Moxeparvovec ,Elevidys ,Dmd Gene Mutation ,